胰腺腺癌患者CD3+和CD8+肿瘤浸润淋巴细胞(til)与预后的关系

Mahshid Panahi , Fereshteh Rezagholizadeh , Shabnam Mollazadehghomi , Pooya Farhangnia , Mohammad Hadi Karbalaie Niya , Hossein Ajdarkosh , Fahimeh Safarnezhad Tameshkel , Seyed Mohammad Heshmati
{"title":"胰腺腺癌患者CD3+和CD8+肿瘤浸润淋巴细胞(til)与预后的关系","authors":"Mahshid Panahi ,&nbsp;Fereshteh Rezagholizadeh ,&nbsp;Shabnam Mollazadehghomi ,&nbsp;Pooya Farhangnia ,&nbsp;Mohammad Hadi Karbalaie Niya ,&nbsp;Hossein Ajdarkosh ,&nbsp;Fahimeh Safarnezhad Tameshkel ,&nbsp;Seyed Mohammad Heshmati","doi":"10.1016/j.ctarc.2023.100699","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><strong>:</strong> Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3<sup>+</sup>/CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.</p></div><div><h3>Materials and Methods</h3><p><strong>:</strong> In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3<sup>+</sup> and CD8<sup>+</sup> TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.</p></div><div><h3>Results</h3><p><strong>:</strong> The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.</p></div><div><h3>Conclusion</h3><p><strong>:</strong> TILs density was high in patients with PDAC. The density of both CD3<sup>+</sup> and CD8<sup>+</sup> TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3<sup>+</sup> and CD8<sup>+</sup> TILs might be effective in predicting PDAC recurrence.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma\",\"authors\":\"Mahshid Panahi ,&nbsp;Fereshteh Rezagholizadeh ,&nbsp;Shabnam Mollazadehghomi ,&nbsp;Pooya Farhangnia ,&nbsp;Mohammad Hadi Karbalaie Niya ,&nbsp;Hossein Ajdarkosh ,&nbsp;Fahimeh Safarnezhad Tameshkel ,&nbsp;Seyed Mohammad Heshmati\",\"doi\":\"10.1016/j.ctarc.2023.100699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><strong>:</strong> Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3<sup>+</sup>/CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.</p></div><div><h3>Materials and Methods</h3><p><strong>:</strong> In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3<sup>+</sup> and CD8<sup>+</sup> TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.</p></div><div><h3>Results</h3><p><strong>:</strong> The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.</p></div><div><h3>Conclusion</h3><p><strong>:</strong> TILs density was high in patients with PDAC. The density of both CD3<sup>+</sup> and CD8<sup>+</sup> TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3<sup>+</sup> and CD8<sup>+</sup> TILs might be effective in predicting PDAC recurrence.</p></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294223000205\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:胰腺腺癌(PDAC)每年导致超过25万人死亡,是全球第八大死亡原因,5年生存率低于5%,中位复发时间为5至23个月。PDAC与CD3+/CD8+肿瘤浸润淋巴细胞(til)、肿瘤扩散程度和临床结果之间的关系最近得到了证实。本研究旨在确定和比较PDAC患者TILs的密度及其与疾病预后的关系。材料与方法:本研究收集64例til阳性PDAC患者的PDAC组织及相应的邻近正常组织。采用免疫组织化学方法检测PDAC组织中CD3+和CD8+ TILs的表达水平。同时,对至少5年的完整随访史进行评估。结果:瘤内和瘤周TILs分别为20例(31.2%)和44例(68.8%)。CD3+ TILs和CD8+ TILs的平均密度分别为67.73%±20.17%和69.45%±17.82%。CD3+ TILs和CD8+ TILs的密度与患者的总生存期、无转移生存期和肿瘤分级无关。然而,肿瘤复发患者的TILs密度明显低于未复发患者。结论:PDAC患者TILs密度较高。肿瘤复发患者的CD3+和CD8+ TILs密度均显著降低。因此,本研究提示,跟踪和测定CD3+和CD8+ til的密度可能有效预测PDAC复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma

Background

: Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3+/CD8+ tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.

Materials and Methods

: In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3+ and CD8+ TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.

Results

: The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3+ TILs and CD8+ TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3+ TILs and CD8+ TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.

Conclusion

: TILs density was high in patients with PDAC. The density of both CD3+ and CD8+ TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3+ and CD8+ TILs might be effective in predicting PDAC recurrence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
期刊最新文献
Clinical and pathological differences between early- and late-onset colorectal cancer and determinants of one-year all-cause mortality among advanced-stage patients: a retrospective cohort study in Medellín, Colombia A case of neoadjuvant chemotherapy in pregnancy with cervical cancer (IB3) Pregnancy-related breast cancer: 14-year experience in a tertiary institution in Hong Kong Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores Tumor circulating biomarkers in colorectal cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1